BridgeBio Pharma (BBIO) Gross Margin (2020 - 2026)
BridgeBio Pharma (BBIO) reported Gross Margin of 94.89% for Q1 2026, down 285.0% on a YoY basis from 51.29% in Q1 2025, and little changed sequentially from 94.74% in Q4 2025.
BridgeBio Pharma (BBIO) Gross Margin (2020 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 7 years of Gross Margin data on file, last reported at 94.89% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 285.0% year-over-year to 94.89%; the trailing twelve-month figure through Mar 2026 stood at 95.13% (down 23.0% YoY), and the FY2025 full-year result was 95.82%, down 243.0% from the prior year.
- Gross Margin was little changed at 94.89% in Q1 2026, from 94.74% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 99.72% in Q1 2024 to a low of 118.64% in Q3 2022.
- A 5-year average of 66.98% and a median of 78.11% in 2024 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin slumped 15661 bps in 2022 and soared 20402 bps in 2023, its largest moves.
- Tracing BBIO's Gross Margin over 5 years: stood at 65.4% in 2022, then gained by 1 bps to 65.73% in 2023, then fell by 2 bps to 64.57% in 2024, then soared by 47 bps to 94.74% in 2025, then grew by 0 bps to 94.89% in 2026.
- Business Quant data shows BBIO's Gross Margin at 94.89% in Q1 2026, 94.74% in Q4 2025, and 94.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn | 94.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.89% |
| Dec 31, 2025 | 94.74% |
| Sep 30, 2025 | 94.56% |
| Jun 30, 2025 | 96.70% |
| Mar 31, 2025 | 97.74% |
| Dec 31, 2024 | 64.57% |
| Sep 30, 2024 | 78.11% |
| Jun 30, 2024 | 72.42% |
| Mar 31, 2024 | 99.72% |
| Dec 31, 2023 | 65.73% |
| Sep 30, 2023 | 85.38% |
| Jun 30, 2023 | 63.50% |
| Mar 31, 2023 | 64.35% |
| Dec 31, 2022 | 65.40% |
| Sep 30, 2022 | -118.64% |
| Jun 30, 2022 | 99.05% |
| Mar 31, 2022 | 20.43% |
| Dec 31, 2021 | 84.49% |
| Sep 30, 2021 | 37.97% |
| Jun 30, 2021 | 99.80% |